The use of fecal microbiota transplant in sepsis

Robert Keskey1, Jennifer T Cone2, Jennifer R DeFazio3

  • 1Section of General Surgery, Department of Surgery, University of Chicago, Chicago, Illinois.

Insights

Fecal microbiota transplant (FMT) shows promise for sepsis by restoring gut bacteria and immune response. However, potential lethal complications mean FMT remains investigational for sepsis treatment.

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Sepsis involves a dysregulated inflammatory response linked to gut microbiota alterations.
  • Critical illness and treatments disrupt gut microbiota diversity and beneficial metabolites like butyrate, creating a pathobiome.
  • This pathobiome contributes to sepsis-induced immune dysfunction and organ failure.

Purpose of the Study:

  • To explore the potential of fecal microbiota transplant (FMT) in treating sepsis.
  • To understand the mechanisms by which FMT may restore immune response and aid sepsis recovery.
  • To highlight the investigational nature of FMT for sepsis due to potential risks.

Main Methods:

  • Review of case series and animal studies on FMT in sepsis.
  • Analysis of FMT's impact on gut microbiota composition and host immune response.
  • Examination of reported complications associated with FMT.

Main Results:

  • Case series suggest FMT can restore immune response and aid sepsis recovery.
  • Animal studies indicate FMT may restore butyrate-producing bacteria and modulate innate immunity for pathogen clearance.
  • Studies also report lethal complications, including bacteremia, with FMT.

Conclusions:

  • FMT shows potential therapeutic benefits in sepsis by modulating the gut microbiota and immune system.
  • Restoration of butyrate-producing bacteria and alteration of innate immunity are proposed mechanisms.
  • FMT for sepsis requires further investigation to understand mechanisms and mitigate risks like bacteremia before clinical application.